Picton Mahoney Asset Management’s Structure Therapeutics GPCR Stock Holding History

Picton Mahoney Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,410	Closed	-$98K	–	427
2023 Q4	$98K	Buy	2,410 +90	+4%	+$5.16K	﹤0.01%	341
2023 Q3	$116K	Buy	+2,320	New	+$74.8K	﹤0.01%	296

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Picton Mahoney Asset Management's GPCR Position: Q1 2024 in Review

Picton Mahoney Asset Management sold out of Structure Therapeutics (GPCR) in Q1 2024, closing a stake of 2,410 shares — an estimated $98K sold.

Picton Mahoney Asset Management first reported a position in GPCR in Q3 2023 and held it in 2 quarters. The position peaked at $116K in Q3 2023. 119 funds tracked by Wall St. Rank hold GPCR as of Q1 2024.

Picton Mahoney Asset Management reported no remaining Structure Therapeutics position as of Q1 2024 after selling out during the quarter.
Picton Mahoney Asset Management sold 2,410 Structure Therapeutics shares in Q1 2024, an estimated $98K.
Picton Mahoney Asset Management first reported a position in Structure Therapeutics in Q3 2023 and held it in 2 quarters.
Picton Mahoney Asset Management's Structure Therapeutics position peaked at $116K in Q3 2023.
119 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2024.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2024, filed 9 May 2024.